Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Preliminary data point to possible link between myocarditis and mRNA COVID-19 vaccines

By Brian Buntz | June 10, 2021

Pfizer-BioNTech vaccine

Image courtesy of Wikipedia

The theme of myocarditis and pericarditis following mRNA vaccination emerged in today’s Vaccines and Related Biological Products Advisory Committee meeting, which reviewed preliminary safety data of Pfizer-BioNTech vaccine in children aged 12 to 15. The risk, however, appears to be small.

As of May 31, there were 116 reports of myocarditis or pericarditis after the first dose of Pfizer-BioNTech vaccine. There were 100 for the first dose of Moderna vaccine. The problem, however, appears to be more common after the second dose. The government has collected 372 reports of myocarditis or pericarditis after the second dose of Pfizer-BioNTech vaccine and 201 for the Moderna vaccine.

Early data suggests a connection between the mRNA vaccines and myocarditis and pericarditis. Out of 2.3 million doses administered to 16-to-17-year-olds, the VAERS database lists 79 cases of myocarditis or pericarditis. The expected rate in a population that size would be between two and 19 cases.

A Pfizer spokesperson said that the company is aware of the reports predominantly in male adolescents and young adults. “According to the CDC, the amount of reports is small given the number of doses administered and patients have typically rapidly improved with conservative treatment,” said Keanna Ghazvini, senior associate, global media relations at Pfizer. “It is important to note that CDC continues to recommend COVID-19 vaccinations for individuals aged 12 and older.”

Pfizer notes that it expects adverse events unrelated to vaccination to occur at a “similar rate in vaccinated individuals as they would in the overall population,” Ghazvini said. “All adverse events are regularly and thoroughly reviewed by Pfizer as well as by CDC,” she continued. “It is important to understand that a careful assessment of the reports is ongoing and it has not been concluded that the mRNA COVID-19 vaccines cause myocarditis or pericarditis. Myocarditis and pericarditis are often caused by viral infections; infection with SARS-CoV-2 has been reported to cause myocarditis.”

Pfizer  supports CDC’s request for “careful assessment of suspected myocarditis and pericarditis cases to further our understanding of the cases reported,” Ghazvini concluded.

One factor to keep in mind is that not all of the currently reported cases of myocarditis and pericarditis are accurate, stressed Dr. Tom Shimabukuro, the deputy director of the Immunization Safety Office at CDC. “It’s a bit of an apples-to-oranges comparison because, again, these are preliminary reports,” he said. “Not all these will turn out to be true myocarditis or pericarditis reports.”

The CDC has scheduled an emergency meeting for June 18 to discuss the reports.

CDC has followed 221 discharged patients with the conditions. Some 81% (180) had a full recovery.

 


Filed Under: Infectious Disease
Tagged With: BioNTech, coronavirus, covid-19, COVID-19 vaccines, FDA, Moderna, Myocarditis, pericarditis, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
Gay couple enjoying life together
World AIDS Day Summit & Celebration slated for early December
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE